Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression
Despite extensive soliciting of AEs for ESK with the US Risk Evaluation and Mitigation Strategy program, respiratory depression is infrequently observed with ESK treatment in the postmarketing setting (estimated incidence: 1 case per 20 000 treatment sessions). Symptoms are manageable and resolve with minor supportive measures. Monitoring for symptoms of respiratory depression, including pulse oximetry, is recommended within the postdose observation period.
Authors
- Richard C. Shelton (ORCID: https://orcid.org/0000-0002-3806-4208)
- Craig Chepke (ORCID: https://orcid.org/0000-0002-4873-4770)
- Gerard Sanacora (ORCID: https://orcid.org/0000-0003-3722-8829)
- N. Parker (ORCID: https://orcid.org/0000-0002-9272-4772)
- Teodora Doherty
- Palina Tsytsik
Institutions
- University of North Carolina at Charlotte (US)
- Johnson & Johnson (United States) (US)
- University of Alabama at Birmingham (US)
- Yale University (US)
- Levine Cancer Institute (US)
- Applied System Technologies (United States) (US)
Publication Details
- Journal
- The International Journal of Neuropsychopharmacology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1093/ijnp/pyae058
- Citations
- 6
- Primary Topic
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Type
- article
- Field-Weighted Citation Impact
- 3.05
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Yale University
- Teva Pharmaceutical Industries
- Valeant Pharmaceuticals International
- Avanir Pharmaceuticals
- Janssen Scientific Affairs
- Vistagen Therapeutics
- Servier
- H. Lundbeck A/S
- Janssen Pharmaceuticals